Geode Capital Management LLC raised its stake in Zura Bio Limited (NASDAQ:ZURA - Free Report) by 70.6% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 912,625 shares of the company's stock after buying an additional 377,545 shares during the period. Geode Capital Management LLC owned 1.36% of Zura Bio worth $3,706,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also recently modified their holdings of the company. Renaissance Technologies LLC boosted its position in Zura Bio by 51.3% during the second quarter. Renaissance Technologies LLC now owns 17,400 shares of the company's stock valued at $61,000 after acquiring an additional 5,900 shares during the last quarter. Bank of New York Mellon Corp boosted its position in shares of Zura Bio by 15.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 47,109 shares of the company's stock valued at $165,000 after purchasing an additional 6,412 shares in the last quarter. Forefront Analytics LLC grew its stake in Zura Bio by 22.1% during the second quarter. Forefront Analytics LLC now owns 41,569 shares of the company's stock worth $145,000 after purchasing an additional 7,531 shares during the period. Healthcare of Ontario Pension Plan Trust Fund acquired a new stake in Zura Bio during the third quarter worth approximately $46,000. Finally, AQR Capital Management LLC acquired a new position in Zura Bio in the second quarter valued at approximately $43,000. Institutional investors own 61.14% of the company's stock.
Wall Street Analysts Forecast Growth
A number of equities research analysts have commented on ZURA shares. Chardan Capital reduced their price target on shares of Zura Bio from $14.00 to $12.00 and set a "buy" rating for the company in a report on Friday, November 8th. Piper Sandler restated an "overweight" rating and issued a $26.00 target price on shares of Zura Bio in a research note on Thursday, September 19th. HC Wainwright reaffirmed a "neutral" rating and issued a $5.00 target price on shares of Zura Bio in a research report on Tuesday, December 24th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Zura Bio in a report on Wednesday, December 11th. Finally, Leerink Partnrs upgraded Zura Bio to a "strong-buy" rating in a report on Monday, November 4th. One analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus price target of $15.80.
Read Our Latest Report on ZURA
Zura Bio Stock Performance
Shares of Zura Bio stock traded down $0.09 on Tuesday, hitting $2.41. The company had a trading volume of 186,590 shares, compared to its average volume of 265,122. Zura Bio Limited has a 1 year low of $2.00 and a 1 year high of $6.35. The stock has a 50 day moving average of $3.07 and a 200-day moving average of $3.59.
Zura Bio (NASDAQ:ZURA - Get Free Report) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.12). Equities analysts anticipate that Zura Bio Limited will post -0.65 earnings per share for the current fiscal year.
Insider Activity at Zura Bio
In related news, Director Parvinder Thiara sold 1,001,633 shares of the stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $2.73, for a total transaction of $2,734,458.09. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 22.10% of the stock is owned by insiders.
Zura Bio Profile
(
Free Report)
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.
Featured Stories
Before you consider Zura Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zura Bio wasn't on the list.
While Zura Bio currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
